A practical reference on c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-29. Anything still debated is marked as such rather than presented as settled.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
In 1979, Bakker and PTL came under investigation by the Federal Communications Commission (FCC) for allegedly misusing funds raised on the air. The FCC report was finalized in 1982 and found that Bakker had raised $350,000 that he told viewers would go towards funding overseas missions but that was actually used to pay for part of Heritage USA. The report also found that the Bakkers used PTL funds for personal expenses. FCC commissioners voted four to three to drop the investigation, after which they allowed Bakker to sell the only TV station that he owned, therefore bypassing future FCC oversight. The FCC forwarded its report to the U.S. Department of Justice, which declined to press charges, citing insufficient evidence. Bakker used the controversy to raise more funds from his audience, branding the investigation a "witch-hunt" and asking viewers to "give the Devil a black eye". A confidential 1985 Internal Revenue Service (IRS) report found that $1.3 million in ministry funds was used for the Bakkers' personal benefit from 1980 to 1983. The report recommended that PTL be stripped of its tax-exempt status, but no action was taken until after the Jessica Hahn scandal broke in 1987. Art Harris and Michael Isikoff wrote in The Washington Post that politics may have played a role in the three government agencies taking no action against PTL despite the evidence against them, as members of the Reagan administration were not eager to go after television ministers whose evangelical followers made up their base.
Hemicelluloses are polysaccharides related to cellulose that comprises about 20% of the biomass of land plants. In contrast to cellulose, hemicelluloses (which include xylans, xyloglucans, (gluco)mannans, and mixed-linkage glucans) are derived from several sugars in addition to glucose, especially xylose but also including mannose, galactose, glucuronic acid, fucose, and arabinose. Hemicelluloses consist of shorter chains – between 500 and 3000 sugar units. Furthermore, hemicelluloses are often branched, whereas cellulose is unbranched.
== Fusion lineage == The formation of all syncytiotrophoblast is from the fusion of two or more cytotrophoblasts via this fusion pathway. This pathway is important because the syncytiotrophoblast plays an important role in fetal-maternal gas exchange, nutrient exchange, and immunological and metabolic functions. An undifferentiated cytotrophoblastic stem cell will differentiate into a villous cytotrophoblast, which is what constitutes primary chorionic villi, and will eventually coalesce into villous syncytiotrophoblast. The formation of syncytiotrophoblast from cytotrophoblast is a terminal differentiation step of trophoblastic cells. Syncytialization of cytotrophoblastic cells can be induced in vitro through multiple signalling molecules including epidermal growth factor, glucocorticoids, and human chorionic gonadotropin.
=== Plot === The game begins with Chell waking up from a stasis bed and hearing instructions from GLaDOS, an artificial intelligence, about upcoming tests. Chell enters into sequential distinct chambers that introduce her to varying challenges to solve using her portal gun, with GLaDOS as her only interaction. GLaDOS promises cake as a reward for Chell if she completes all the test chambers. As Chell nears completion, GLaDOS's motives and behavior turn more sinister, suggesting insincerity and callous disregard for the safety and well-being of test subjects. The test chambers become increasingly dangerous as Chell proceeds, including a live-fire course designed for military androids, as well as chambers flooded with a hazardous liquid. In one chamber, GLaDOS forces Chell to "euthanize" a Weighted Companion Cube in an incinerator, after Chell uses it for assistance. After Chell completes the final test chamber, GLaDOS maneuvers Chell into an incinerator in an attempt to kill her. Chell escapes with the portal gun and makes her way through the maintenance areas within the Enrichment Center. GLaDOS panics and insists that she was pretending to kill Chell as part of testing, while it becomes clear that GLaDOS had previously killed all the inhabitants of the center. Chell travels further through the maintenance areas, discovering dilapidated backstage areas covered in graffiti that includes statements such as "the cake is a lie", and pastiches of quotes from famous poets such as Henry Wadsworth Longfellow and Emily Brontë.
=== Solution-diffusion model === In the solution-diffusion model, transport occurs only by diffusion. The component that needs to be transported must first be dissolved in the membrane. The general approach of the solution-diffusion model is to assume that the chemical potential of the feed and permeate fluids are in equilibrium with the adjacent membrane surfaces such that appropriate expressions for the chemical potential in the fluid and membrane phases can be equated at the solution-membrane interface. This principle is more important for dense membranes without natural pores such as those used for reverse osmosis and in fuel cells. During the filtration process a boundary layer forms on the membrane. This concentration gradient is created by molecules which cannot pass through the membrane. The effect is referred to as concentration polarization and, occurring during the filtration, leads to a reduced trans-membrane flow (flux). Concentration polarization is, in principle, reversible by cleaning the membrane which results in the initial flux being almost totally restored. Using a tangential flow to the membrane (cross-flow filtration) can also minimize concentration polarization.
Sources: en.wikipedia.org
1961), author of Penguin Books Users: How Big Tech Took Control and How to Fight Back; filmmaker, politician and social activist; advocate for children's rights in the digital world; establishing standards for online safety and privacy across the world; sits as a crossbench peer in the United Kingdom's House of Lords; she is an advisor to the Institute for Ethics of artificial intelligence at Oxford University, a commissioner on the Broadband Commission for Sustainable Development, and founder of 5Rights Foundation; sister of record producer Adam Kidron; daughter of British Israeli of South African origin, Michael Kidron, founder of leftist Pluto Press; niece of Socialist Workers Party founder Tony Cliff and activist Chanie Rosenberg, and the cousin of historian Donny Gluckstein.; appointed Officer of the Order of the British Empire (OBE) in the 2012 Birthday Honours for services to drama. Sophia King (later Fortnum; b. 1781/2, d. in or after 1805) Gothic novelist and poet, and sister of Gothic writer Charlotte Dacre. She contributed to poetry periodicals under the nom-de-plume "Sappho".
=== Cancer === Depending on the type of cancer presented and the context, galectin-7 can either be helpful to suppress cancer or promote the cancer. What is suppressive of one tissue, such as the stomach, may be promotive in another, such as breast cancer or in the oral epithelium. It can up regulate by p53, making it a part of the pro-apoptotic network, however this can still be part of a promoter of tumors if apoptosis goes unregulated. P53 status is noted in cancers because of the chance for a mutant p53 where the balance of apoptosis processes could shift to metastasis. In some cancers, the protein enhances apoptosis through mitochondrial pathways, and disruption of survival signaling. There have been observations to suggest a correlation between tumor progression and human lumphoid disease as well because of an accumulation of galectin-7 with no expression detected in normal tissue where it is normally found. Galectin-7 has been mainly studies under carcinoma cancers and have shown how they are associated with a decrease in galectin-7 expression however, squamous epithelial and mucous tumors still express higher galectin-7 levels than normal tissues in cancers having to do with the head and neck. This displays how over expression and under expression of galectin-7 can be cause for concern when it comes to developing cancers in the body. The protein has also been found to down regulate, meaning the tumor cells have a reduced expression of galectin-7, producing an association, not necessarily causation, to poor tumor differentiation.
== References == Arsdel, Wallace, B. Van, Michael, J Copley, and Robert, L. Olson. Quality and Stability of Frozen Foods: Time-Temperature Tolerance and its Significance. New York, NY: John Wiley & Sons, INC, 1968. "Clarence Birdseye." Encyclopedia of World Biography. Vol. 19. 2nd ed. Detroit: Gale, 2004. 25–27. Gale Virtual Reference Library. Gale. Brigham Young University – Utah. 3 November 2009. (subscription required) Copson, David. Microwave Heating. 2nd ed.. Westport, CT: The AVI Publishing Company, INC., 1975. Decareau, Robert. Microwave Foods: New Product Development. Trumbull, CT: Food & Nutrition Press, INC., 1992. Gould, Grahame. New Methods of Food Preservation. New York, NY: Chapman & Hall, 2000. Mathlouthi, Mohamed. Food Packaging and Preservation. New York, NY: Chapman & Hall, 1994.*^Robinson, Richard. Microbiology of Frozen Foods. New York, NY: Elsevier Applied Science Publishers LTD, 1985. Russell, Nicholas J., and Grahame W. Gould. Food Preservatives. 2nd ed. New York, NY: Kluwer Academic/Plenum Publishers, New York, 2003. Sun, Da-Wen. Handbook of Frozen Food Processing and Packaging. Boca Raton, Fl: Taylor & Francis Group, LLC, 2006. Tressler, Donald K., Clifford F. Evers, and Barbara, Hutchings Evers. Into the Freezer – and Out. 2nd ed. New York, NY: The AVI Publishing Company, INC., 1953. Tressler, Donald K., and Clifford F. Evers. The Freezing Preservation of Foods. 3rd ed. 1st volume. Westport, CT: The AVI Publishing Company, INC., 1957. Whelan, Elizabeth M., and Fredrick J. Stare. Panic in the Pantry: Facts and Fallacies About the Food You Buy.
==== Almond tofu ==== "Almond tofu" (Chinese: 杏仁豆腐 xìngrén dòufu; Japanese: annindōfu) is a milky white and gelatinous substance resembling tofu, but it does not use soy products or soy milk and is hardened with agar. A similar dessert made with coconut milk or mango juices may occasionally be referred to as "coconut tofu" or "mango tofu", although such names are also given to hot dishes that use soy tofu and coconut or mango in the recipe.
== See also == Phenolic compounds in wine Other positional isomers: Isovanillin ortho-Vanillin 2-Hydroxy-5-methoxybenzaldehyde 2-Hydroxy-4-methoxybenzaldehyde Benzaldehyde Protocatechuic aldehyde Syringaldehyde
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.